Publikation

Survival of recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients (pts) treated in 1st or 2nd line with an anti-EGFR-antibody (EAB)

Präsentation/Vortrag - 10.10.2015

Siano Marco